News – Page 1103 – Endpoints News

GSK shares hit as analyst touts potential of Merck’s experimental HIV drug; Interleukin Genetics slashes staff; ...

8 years ago

Fast-moving Sienna Bio vaults from buyout to B round to $75M IPO

8 years ago

Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII

8 years ago

In latest setback, another Coherus partner bails out on Amgen biosimilar deal

8 years ago

A judge orders Martin Shkreli to zip it -- after Twitter shuts down his latest online account

8 years ago

Allergan vet Ingram takes the helm at Sarepta; Big Pharma alumni Catherine Steele is the new comms chief at Biogen

8 years ago

Merck left the door open to a devastating cyberattack, missing two chances to raise a defense

8 years ago

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

8 years ago

Gilead buy Vertex? A golden oldie in the M&A buzz circuit gets fresh air time

8 years ago

Far from the big hubs, Apellis is steering its rival to Alexion's Soliris into a PhIII program

8 years ago

Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?

8 years ago

Cara tries hard to spin the data, but key PhIIb pain study fails and shares slide south

8 years ago

AstraZeneca and China partner Chi-Med launch a global PhIII; Zai Lab bags $30M for R&D effort

8 years ago

Another biotech IPO boasting a pharma castoff rings the bell on Wall Street with $75M haul

8 years ago

Omeros fires back after an online short attack whittles down its shares

8 years ago

Investors — and AstraZeneca CEO Pascal Soriot — are getting a tad nervous as MYSTIC data loom

8 years ago

Atlas Venture vows to keep doing well by doing good with its new, $350M biotech fund

8 years ago

Genius or chronic liar? The Martin Shkreli fraud trial gets underway with two radically opposed portraits

8 years ago

Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta

8 years ago

Coherus restructures, axes 51 staffers in wake of an FDA rejection of its knockoff of Amgen’s Neulasta

8 years ago

Gene therapy upstart lands $45M round; Biogen picks new communications chief

8 years ago

Merck was hit hard by a vicious cyberattack yesterday. Here is what we know.

8 years ago

Mersana scores a $75M IPO as Wall Street continues to embrace biotech

8 years ago

Hammered on a gene therapy setback, Dimension cuts staff and circles the wagons

8 years ago

First page Previous page 1100 1101 110211031104 1105 1106 Next page Last page